R&D in the Pharmaceutical Industry: A World of Small Innovations
30 Pages Posted: 20 Jul 2007
Date Written: December 2005
Abstract
It is commonly argued that in recent years pharmaceutical companies have directed their R&D towards small improvements of existing compounds instead of more risky drastic innovations. In this paper we show that the proliferation of these small innovations is likely to be linked to the lack of market sensitivity of a part of the demand to changes in prices. Compared to their social contribution, small innovations are relatively more profitable than large ones because they are targeted to the smaller but more inelastic part of the demand. We also study the effect of regulatory instruments such as price ceilings, copayments and reference prices and extend the analysis to competition in research.
Keywords: Health-care, pharmaceuticals, innovation
JEL Classification: I11, I18, L51, O31
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Higher Prices from Entry: Pricing of Brand-Name Drugs
By Jeffrey M. Perloff, Valerie Y. Suslow, ...
-
By Ernst R. Berndt, Linda Tm Bui, ...
-
Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
By Ernst R. Berndt, Robert S. Pindyck, ...
-
Generic Drug Industry Dynamics
By David Reiffen and Michael R. Ward
-
Hedonic Analysis of Arthritis Drugs
By Iain M. Cockburn and Aslam H. Anis
-
Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade
By Henry G. Grabowski and John M. Vernon